Uncertainty over US biz growth keeps Street cautious on Lupin stock

A strong product pipeline and growth in India and emerging markets are positives, but regulatory hurdles, delayed drug approvals in the US could hurt prospects

A day after Lupin signed a second partnership deal for its oncology drugs, the stock gained over 3 per cent. While the Street sentiment remains strong on the prospects of Lupin’s India business, uncertainties over growth in the US are keeping analysts cautious about the stock. 

Lupin’s latest partnership with Boehringer Ingelheim to develop and commercialise a novel oncology drug is a positive step. This should help it in developing a strong oncology pipeline for the world’s largest health care market — the US. 

Lupin has also been investing in developing other specialty portfolios such as respiratory, gynaecology, biosimilars, injectables,